m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02995)
Name
G749
Synonyms
G-749
    Click to Show/Hide
Status
Investigative
Structure
Formula
C25H25BrN6O2
InChI
1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)
InChIKey
SXWMIXPJPNCXQQ-UHFFFAOYSA-N
PubChem CID
78357765
TTD Drug ID
D0N3XP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Tyrosine-protein kinase Mer (MERTK)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for G749. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of G749 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for G749. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of G749 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). [1], [2]
References
Ref 1 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 2 UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77. doi: 10.1158/1535-7163.MCT-13-0040. Epub 2013 Aug 30.